NEW HAVEN, Conn., Feb. 5 /PRNewswire/ -- Achillion Pharmaceuticals,
Inc. today announced that John C. Pottage, M.D., Achillion's Chief Medical
Officer, will participate in a panel discussion on Monday, February 12 at
the 2007 BIO CEO and Investor Conference in New York City. The panel is a
Therapeutic Workshop scheduled for 3:30 p.m. (EST) entitled, "Novel HIV
Therapies." Details about the conference, including webcast information,
can be found on the conference website at http://www.ceo.bio.org.
About Achillion
Achillion is a biopharmaceutical company focused on the discovery,
development and commercialization of innovative treatments for infectious
diseases. Achillion is currently developing treatments for HIV infection,
chronic hepatitis C infection and serious hospital-based bacterial
infections. For more information on Achillion Pharmaceuticals, please visit
the company's web site at http://www.achillion.com or call Achillion at
1-203-624-7000.
Contact:
Mary Kay Fenton
Achillion Pharmaceuticals, Inc.
Tel. (203) 624-7000
mfenton@achillion.com
Media:
Kari Watson
MacDougall Biomedical Communications, Inc.
Tel. (508) 647-0209
kwatson@macbiocom.com
SOURCE Achillion Pharmaceuticals, Inc.
 back to top
Related links:
http://www.macbiocom.com
http://www.ceo.bio.org http://www.achillion.com
CONTACT:
Mary Kay Fenton of Achillion Pharmaceuticals,
Inc., +1-203-624-7000, or mfenton@achillion.com, or Media, Kari
Watson, of MacDougall Biomedical Communications, Inc.,
+1-508-647-0209, or kwatson@macbiocom.com, for Achillion
Pharmaceuticals, Inc.
|
